Navigating the ARA-290 price landscape requires evaluating synthesis quality, mass spectrometry verification, and endotoxin thresholds rather than comparing surface-level retail costs. As an erythropoietin-derived peptide engineered for innate repair receptor targeting, high-purity ARA-290 demands rigorous analytical validation to ensure reproducible results in preclinical inflammatory signaling and tissue-protection assays.
Navigating the ARA-290 price landscape requires evaluating synthesis quality, mass spectrometry verification, and endotoxin thresholds rather than comparing surface-level retail costs. As an erythropoietin-derived peptide engineered for innate repair receptor targeting, high-purity ARA-290 demands rigorous analytical validation to ensure reproducible results in preclinical inflammatory signaling and tissue-protection assays.
The market ARA-290 price for laboratory-grade material typically reflects the rigorous chemical synthesis, sequence fidelity verification, and purification steps required to yield a stable 11-amino acid peptide. Researchers evaluating supplier quotes must look beyond the initial cost per milligram and assess the underlying quality controls, including reverse-phase high-performance liquid chromatography (RP-HPLC), electrospray ionization mass spectrometry (ESI-MS), and Limulus Amebocyte Lysate (LAL) endotoxin quantification.
When acquiring research-grade ARA-290, price variances across vendors primarily stem from differences in solid-phase peptide synthesis (SPPS) standards, trifluoroacetic acid (TFA) counter-ion removal efficiency, and lot-specific certification. Low-cost alternatives often omit comprehensive third-party testing, introducing unquantified impurities that can confound cell culture assays and animal models. Institutional buyers seeking consistent baseline conditions rely on suppliers that provide fully documented certificates of analysis (COAs) from ISO 17025 accredited laboratories.
ARA-290, structurally designated as Cibinetide, is a synthetic 11-amino acid peptide derived from the spatial structure of helix B in erythropoietin (EPO). Native EPO interacts with both homodimeric erythropoietin receptors (EPOR₂)—which stimulate erythropoiesis—and heterodimeric innate repair receptors (IRR). ARA-290 was designed to selectively bind the IRR complex while entirely lacking affinity for the classical EPOR₂ homodimer.
Because of this targeted sequence configuration, research models utilizing ARA-290 can isolate tissue-protective and anti-inflammatory signaling cascades without inducing red blood cell proliferation or altering hematocrit levels. Preclinical research demonstrates that this structural selectivity makes ARA-290 a vital tool for studying localized cellular stress responses without triggering systemic hematopoietic changes. Investigators can review broader structural classifications within our research library hub.
The innate repair receptor (IRR) is a heterotrimeric complex composed of two erythropoietin receptor subunits and two common beta receptor (CD131) subunits (EPOR₂-βc₂). Under normal physiological conditions, the IRR is expressed at low baseline levels. However, during tissue injury, metabolic stress, or exposure to pro-inflammatory cytokines, cellular expression of the IRR is rapidly upregulated across parenchymal, endothelial, and neuronal tissues.
Binding of ARA-290 to the IRR initiates an intracellular signaling cascade that inhibits nuclear factor kappa B (NF-κB) nuclear translocation. In vitro assays demonstrate that this inhibition subsequently downregulates the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Simultaneously, IRR activation stimulates anti-apoptotic signaling pathways via the phosphorylation of Akt and extracellular signal-regulated kinase (ERK), promoting cellular survival in compromised tissue environments.
In preclinical literature, ARA-290 is extensively evaluated in models of peripheral neuropathy, microvascular damage, and ischemia-reperfusion injury. Rodent models of diabetic neuropathy demonstrate that administration of IRR agonists correlates with reduced microglial activation within the spinal cord, diminished intraepidermal nerve fiber loss, and structural preservation of small unmyelinated nerve fibers.
Furthermore, in vitro endothelial cultures subjected to hypoxic or metabolic stress exhibit enhanced capillary-like tube formation and reduced apoptosis when exposed to ARA-290. Investigators studying systemic metabolic dysfunction frequently analyze how IRR activation mitigates chronic low-grade inflammation in pancreatic islet and renal tubular cell lines, establishing ARA-290 as a versatile compound for multi-systemic tissue-protection studies.
The primary cost drivers governing the true ARA-290 price involve the complexity of solid-phase peptide synthesis (SPPS), double-coupling steps to prevent deletion sequences, and stringent post-synthesis purification protocols. Achieving a purity threshold exceeding 98% requires multiple RP-HPLC purification cycles, which significantly reduces total peptide yield but ensures the removal of truncated fragments and organic synthesis byproducts.
Additionally, specialized processing to remove residual trifluoroacetic acid (TFA)—a common artifact of cleavage protocols that exhibits cellular toxicity in delicate cell culture assays—increases production overhead. Academic and commercial laboratories utilizing our wholesale program benefit from bulk synthesis efficiencies that lower the unit price while maintaining mandatory ISO 17025 analytical verification across every production lot.
To ensure experimental reproducibility, researchers must verify that every lot of ARA-290 is supported by a authentic Certificate of Analysis. PX1 Research subjects all lot batches to rigorous analytical protocols conducted by independent third-party laboratories. HPLC chromatograms must confirm chemical purity of ≥98.0%, demonstrating sharp single-peak resolution without co-eluting impurities.
Mass spectrometry (ESI-MS) is performed concurrently to verify the exact molecular weight against the theoretical mass of the ARA-290 peptide sequence, confirming sequence fidelity. Crucially, because bacterial endotoxins can activate NF-κB and confound inflammatory pathway research, PX1 Research subjects all peptides to LAL endotoxin testing, ensuring levels remain well below standard cell culture toxicity thresholds (<0.01 EU/mg). Explore our complete catalog of analytical-grade compounds in our all peptides hub.
When designing protocols focused on tissue defense and cell survival, investigators often compare ARA-290 against alternative cytoprotective peptides within adjacent research classes. While ARA-290 acts specifically via the heterodimeric innate repair receptor to modulate NF-κB and apoptotic signaling, compounds like BPC-157 target growth factor upregulation, focal adhesion kinase (FAK), and nitric oxide synthase pathways to facilitate tissue repair. Similarly, TB-500 acts primarily through actin-sequestration mechanisms to enhance cell migration, while KPV operates via alpha-MSH receptor pathways to suppress acute inflammatory responses. Selecting the appropriate compound depends entirely on whether the experiment targets IRR-mediated transcriptomic changes or alternate structural and repair pathways.
ARA-290 is supplied as a lyophilized (freeze-dried) powder to maintain structural stability during transit and storage. Upon receipt, lyophilized vials should be stored at -20°C for short-term projects or -80°C for long-term storage, protected from light exposure and moisture ingress. Repeated freeze-thaw cycles must be strictly avoided to prevent peptide degradation.
For reconstitution in laboratory environments, sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4) should be gently introduced against the inner glass wall of the vial. The solution should be gently swirled—never vortexed or vigorously shaken—until full dissolution is achieved. Reconstituted aliquots must be stored at 2°C to 8°C and utilized within documented stability windows to maintain target concentration integrity during in vitro assays.
PX1 Research is dedicated to providing institutional, academic, and private laboratories with chemical compounds manufactured to exact specifications. Our ARA-290 is produced in GMP-compliant facilities within the USA, ensuring strict adherence to environmental controls, batch consistency, and chain-of-custody documentation.
Orders placed before daily cutoff times ship same-day from our primary distribution hubs in California and Arizona, minimizing transit times and cold-chain exposure. By combining lot-specific HPLC/MS verification, stringent endotoxin monitoring, and clear volume pricing, PX1 Research serves as a trusted supplier for advanced innate repair receptor peptides and broader laboratory applications.
What key factors determine the ARA-290 price for laboratory procurement?
The ARA-290 price is determined by solid-phase synthesis complexity, purity thresholds (≥98%), TFA counter-ion exchange, lot-specific RP-HPLC and ESI-MS validation, endotoxin testing, and bulk order volume.
What is the primary mechanism of ARA-290 in preclinical research?
ARA-290 selectively binds the innate repair receptor (IRR)—a EPOR₂-βc₂ heterodimer—inhibiting NF-κB nuclear translocation and downregulating pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 without stimulating erythropoiesis.
How does ARA-290 differ from native erythropoietin (EPO)?
Native EPO binds both EPOR₂ homodimers (stimulating red blood cell production) and IRR heterodimers. ARA-290 is sequence-engineered to interact exclusively with the IRR, isolating tissue-protective signaling without altering hematocrit.
Does PX1 Research provide analytical verification for ARA-290?
Yes. Every lot of ARA-290 from PX1 Research includes a third-party Certificate of Analysis (COA) from an ISO 17025 accredited laboratory detailing RP-HPLC purity, ESI-MS sequence validation, and LAL endotoxin testing.
What reconstituted stability parameters apply to ARA-290?
Once reconstituted in sterile PBS or bacteriostatic water, liquid aliquots should be kept at 2°C–8°C for short-term use. Avoid repeated freeze-thaw cycles and mechanical agitation like vortexing.
Is ARA-290 approved for human administration or therapeutic use?
No. ARA-290 provided by PX1 Research is strictly sold as a research compound for laboratory research use only. It is not intended for human consumption, clinical use, or veterinary administration.
How is ARA-290 shipped to maintain peptide integrity?
PX1 Research ships lyophilized peptides same-day (Monday through Friday) from facilities in California and Arizona, utilizing temperature-controlled packing protocols to ensure compound stability during transit.
Where can laboratories purchase bulk volumes of ARA-290?
Institutional buyers and principal investigators can request bulk volume tier pricing directly through the PX1 Research wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.